Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort

European Journal of Cancer Prevention

Volumn 18, Issue 5, 2009, Pages 381-384

  Gatenby, Piers A ^a   Ramus, James R ^a   Caygill, Christine P ^a   Winslet, Marc C ^a   Watson, Anthony ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adenocarcinoma; Aspirin; Barrett's oesophagus; Chemoprevention; Oesophageal cancer; Prevention

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTICARCINOGENIC AGENTS; ASPIRIN; BARRETT ESOPHAGUS; COHORT STUDIES; DEMOGRAPHY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 69749083191     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32832e0955     Document Type: Article

References (17)

1. Anderson LA, Johnson BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, et al. (2006). Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 66:4975-4982.
2. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. (2000). Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 9:119-123. (Pubitemid 30062918)
3. Corley DA, Kerlikowske K, Verma R, Buffler P (2003). Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124:47-56. (Pubitemid 36055338)
4. De Jonge PJ, Steverberg EW, Kuipers EJ, Honkoop P, Wolters LM, Kerkhof M, et al. (2006). Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 101:1421-1429. (Pubitemid 43980612)
5. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. (2007). NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4:e67.
6. Gatenby PAC, Caygill CPJ, Ramus JR, Charlett A, Watson A (2008). Barrett's columnar-lined oesophagus: demographic associations and adenocarcinoma risk. Dig Dis Sci 53:1175-1185.
7. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, et al. (2007). Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99:545-557. (Pubitemid 47073557)
8. Hur C, Nishioka NS, Gazelle GS (2004). Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96:316-325. (Pubitemid 38256276)
9. Hur C, Broughton DE, Ozanne E, Yachimski P, Nishioka NS, Gazelle GS (2008). Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 103:2432-2442.
10. Jacobson GA, Narkowicz C, Lord R, Howard BJ, Chung S (2007). Effect of celecoxib on cyclooxygenase-2 expression and possible variants in a patient with Barrett's esophagus. Dis Esophagus 20:265-268. (Pubitemid 46831261)
11. Jankowski J, Moayyedi P (2004). Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96:885-887.
12. Lagergren J (2006). Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol 20:803-812.
13. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001). Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96:990-996. (Pubitemid 32319127)
14. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, et al. (2005). Proinflammatory cytokine and nuclear factor kappa-b expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100:1257-1264. (Pubitemid 40904346)
15. Tsibouris P, Hendrickse MT, Isaacs PE (2004). Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther 20:645-655. (Pubitemid 39279053)
16. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. (2005). Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6:945-952. (Pubitemid 41685227)
17. Watson A (2000). Barrett's oesophagus - 50 years on. Br J Surg 87:529-531.